Cargando…
Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders
Spherical nucleic acids (SNAs) are nanostructures consisting of nucleic acids in a spherical configuration, often around a nanoparticle core. SNAs are advantageous as gene-regulating agents compared to conventional gene therapy owing to their low toxicity, enhanced stability, uptake by virtually any...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693734/ https://www.ncbi.nlm.nih.gov/pubmed/33147737 http://dx.doi.org/10.3390/ph13110360 |
_version_ | 1783614813477273600 |
---|---|
author | Holmes, Thomas R. Paller, Amy S. |
author_facet | Holmes, Thomas R. Paller, Amy S. |
author_sort | Holmes, Thomas R. |
collection | PubMed |
description | Spherical nucleic acids (SNAs) are nanostructures consisting of nucleic acids in a spherical configuration, often around a nanoparticle core. SNAs are advantageous as gene-regulating agents compared to conventional gene therapy owing to their low toxicity, enhanced stability, uptake by virtually any cell, and ability to penetrate the epidermal barrier. In this review we: (i) describe the production, structure and properties of SNAs; (ii) detail the mechanism of SNA uptake in keratinocytes, regulated by scavenger receptors; and (iii) report how SNAs have been topically applied and intralesionally injected for skin disorders. Specialized SNAs called nanoflares can be topically applied for gene-based diagnosis (scar vs. normal tissue). Topical SNAs directed against TNFα and interleukin-17A receptor reversed psoriasis-like disease in mouse models and have been tested in Phase 1 human trials. Furthermore, SNAs targeting ganglioside GM3 synthase accelerate wound healing in diabetic mouse models. Most recently, SNAs targeting toll-like receptor 9 are being used in Phase 2 human trials via intratumoral injection to induce immune responses in Merkel cell and cutaneous squamous cell carcinoma. Overall, SNAs are a valuable tool in bench-top and clinical research, and their advantageous properties, including penetration into the epidermis after topical delivery, provide new opportunities for targeted therapies. |
format | Online Article Text |
id | pubmed-7693734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76937342020-11-28 Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders Holmes, Thomas R. Paller, Amy S. Pharmaceuticals (Basel) Review Spherical nucleic acids (SNAs) are nanostructures consisting of nucleic acids in a spherical configuration, often around a nanoparticle core. SNAs are advantageous as gene-regulating agents compared to conventional gene therapy owing to their low toxicity, enhanced stability, uptake by virtually any cell, and ability to penetrate the epidermal barrier. In this review we: (i) describe the production, structure and properties of SNAs; (ii) detail the mechanism of SNA uptake in keratinocytes, regulated by scavenger receptors; and (iii) report how SNAs have been topically applied and intralesionally injected for skin disorders. Specialized SNAs called nanoflares can be topically applied for gene-based diagnosis (scar vs. normal tissue). Topical SNAs directed against TNFα and interleukin-17A receptor reversed psoriasis-like disease in mouse models and have been tested in Phase 1 human trials. Furthermore, SNAs targeting ganglioside GM3 synthase accelerate wound healing in diabetic mouse models. Most recently, SNAs targeting toll-like receptor 9 are being used in Phase 2 human trials via intratumoral injection to induce immune responses in Merkel cell and cutaneous squamous cell carcinoma. Overall, SNAs are a valuable tool in bench-top and clinical research, and their advantageous properties, including penetration into the epidermis after topical delivery, provide new opportunities for targeted therapies. MDPI 2020-11-02 /pmc/articles/PMC7693734/ /pubmed/33147737 http://dx.doi.org/10.3390/ph13110360 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Holmes, Thomas R. Paller, Amy S. Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders |
title | Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders |
title_full | Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders |
title_fullStr | Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders |
title_full_unstemmed | Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders |
title_short | Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders |
title_sort | gene regulation using spherical nucleic acids to treat skin disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693734/ https://www.ncbi.nlm.nih.gov/pubmed/33147737 http://dx.doi.org/10.3390/ph13110360 |
work_keys_str_mv | AT holmesthomasr generegulationusingsphericalnucleicacidstotreatskindisorders AT palleramys generegulationusingsphericalnucleicacidstotreatskindisorders |